Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care

Regorafenib is an oral multikinase inhibitor that inhibits several kinases relevant to tumor biology in several cancers, including colorectal carcinoma (CRC) and gastrointestinal stromal tumor (GIST). In phase III trials, regorafenib significantly improved overall survival versus placebo in patients...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Grothey, Axel, George, Suzanne, van Cutsem, Eric, Blay, Jean-Yves, Sobrero, Alberto, Demetri, George D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2014
Aiheet:
Symptom Management and Supportive Care
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4041675/
https://ncbi.nlm.nih.gov/pubmed/24821824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0059
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia